BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
Recruiting · NCT05370430 · Registry updated 2025-11-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL | B-cell neoplasm, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm | Recruiting | Phase 1 | 2025-11-20 | NCT05370430 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| City of Hope Medical Center | 347 |
| PeproMene Bio, Inc. | 2 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Atrium Health Levine Cancer Institute - Morehead | Charlotte | United States | 1 |
| City of Hope Medical Center | Duarte | United States | 313 |
| Providence Swedish Cancer Institute | Seattle | United States | 1 |
| Stanford University | Stanford | United States | 213 |
| University of Kansas Hospital | Kansas City | United States | 24 |
| University of Minnesota | Minneapolis | United States | 325 |